SCHEMBL22355227

SCHEMBL22355227

CC(C)OC(=O)[C@H](CCC(=O)OCc1ccccc1)NC(=O)OC(C)(C)C

nearest known ligand 0.54

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
PPARA Q07869 3/20 0.54
CTSS P25774 4/20 0.51
KLK7 P49862 4/20 0.49
KLK5 Q9Y337 3/20 0.49
PPARG P37231 2/20 0.49
SYK P43405 1/20 0.48
CTSK P43235 5/20 0.47
ACE P12821 1/20 0.47
CTSL P07711 1/20 0.47
CTSB P07858 1/20 0.47
TLR2 O60603 1/20 0.46
TLR1 Q15399 1/20 0.46
MEN1 O00255 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
KMT2A Q03164 1/20 0.46
MAPT P10636 1/20 0.46
CASP1 P29466 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22355228 1.00 PPARA (0.54) PPARACTSSKLK7KLK5PPARG
SCHEMBL22355211 0.91 CTSK (0.51) PPARACTSSSYKCTSKCTSL
SCHEMBL3817109 0.91 PPARA (0.55) PPARACTSSKLK7KLK5PPARG
SCHEMBL1517760 0.91 PPARA (0.55) PPARACTSSKLK7KLK5PPARG
SCHEMBL2011835 0.91 PPARA (0.55) PPARACTSSKLK7KLK5PPARG
SCHEMBL13007476 0.91 PPARA (0.55) PPARACTSSKLK7KLK5PPARG
SCHEMBL27905048 0.90 PPARA (0.53) PPARACTSSKLK7KLK5PPARG
SCHEMBL10587650 0.90 KLK7 (0.54) PPARACTSSKLK7KLK5PPARG
SCHEMBL2301376 0.90 PPARA (0.54) PPARACTSSKLK7KLK5PPARG
SCHEMBL19020373 0.90 PPARA (0.54) PPARACTSSKLK7KLK5PPARG

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12240797-B2 Method of preparing a DON prodrug from L-glutamic acid DRACEN PHARMACEUTICALS, INC. (US) 2025-03-04 US disclosed
US-20220089522-A1 METHOD OF PREPARING A DON PRODRUG FROM L-GLUTAMIC ACID DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT 2022-03-24 US disclosed
WO-2020167831-A1 METHOD OF PREPARING A DON PRODRUG FROM L-GLUTAMIC ACID DRACEN PHARMACEUTICALS, INC. (US) 2020-08-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220089522-A1 METHOD OF PREPARING A DON PRODRUG FROM L-GLUTAMIC ACID GLUL, GLRA1, GRIN1 PPARA 2196/4885CTSS 3858/4885KLK7 3602/4885
US-12240797-B2 Method of preparing a DON prodrug from L-glutamic acid GLUL, GLRA1, GLS PPARA 2058/4885CTSS 3765/4885KLK7 3498/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.